Colorado is currently home to 1774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Total Joint Arthroplasty in a Pediatric Population
NCT04294693
Recruiting
The primary purpose of this study is to examine the functional ability and quality of life in those patients who received a total joint arthroplasty (TJA) for reasons other than having a solid tumor at the location of the joint.
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
09/10/2024
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Total Joint Arthroplasty
Register for Updates
Biomarkers of Immune-Related Toxicity
NCT03409016
Recruiting
This is a single-center, correlative pilot study evaluating potential biomarkers predictive of immune-related adverse events associated with immune checkpoint inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/10/2024
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Cancer, Metastatic Cancer
Register for Updates
An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App
NCT06098482
Recruiting
The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Denver Research and Technology Labs, Lone Tree, Colorado
Conditions: Hearing Loss
Register for Updates
Feasibility of Cough Monitoring in Children
NCT06587126
Recruiting
Cystic fibrosis (CF) is a disease characterized by chronic airway infection and impaired mucociliary clearance, which predisposes those affected to recurrent pulmonary exacerbations (PEx) and progressive decline in lung function. Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) results in decreases in patient-reported cough and PEx. Despite this, increased cough remains the most common symptom associated with acute PEx and worsening lung disease. Cough frequency was historically difficult t... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
09/04/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Cystic Fibrosis in Children
Register for Updates
International Weight Control Registry
NCT04907396
Recruiting
The IWCR is a global scientific study aimed at better understanding the opportunities and barriers for reducing the prevalence of obesity by collecting information from people who have experience with weight management in their everyday lives. The investigators seek to gather information on a wide range of weight management experiences, ranging from weight loss and weight loss maintenance to weight gain and inability to lose weight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Colorado, Denver, Denver, Colorado
Conditions: Weight Loss, Overweight, Obesity
Register for Updates
The PREDICT Registry:
NCT03448926
Recruiting
This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.
Gender:
FEMALE
Ages:
Between 30 years and 85 years
Trial Updated:
09/03/2024
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: DCIS
Register for Updates
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Recruiting
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: University of Colorado Denver, Aurora, Colorado
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes
Register for Updates
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
NCT01694940
Recruiting
The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Register for Updates
Neuroblastoma Biology Study
NCT01587300
Recruiting
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More
Gender:
ALL
Ages:
Between 31 days and 99 years
Trial Updated:
09/01/2024
Locations: Children Hospital of Colorado, Aurora, Colorado
Conditions: Neuroblastoma
Register for Updates
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
NCT06582017
Recruiting
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical start... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Sarah Cannon Research Institute - Denver DDU, Denver, Colorado
Conditions: Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
Register for Updates
ENCALM: a Study of ENX-102 As a Monotherapy Treatment in Patients with Generalized Anxiety Disorder
NCT05749055
Recruiting
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/29/2024
Locations: Mountain View Clinical Research, Denver, Colorado
Conditions: Generalized Anxiety Disorder
Register for Updates
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT05637216
Recruiting
This study will evaluate the efficacy of losartan (LOS), an FDA-approved transforming growth factor beta-1 (TGF-β1) blocker, to decrease radiation induced fibrosis (RIF) in the breast and the lung of breast cancer patients, testing the hypothesis that Losartan will decrease RIF, TGF- β1 and cellular senescence/inflammation in the breast and the lung of irradiated breast cancer patients relative to placebo treatment and consequently improve clinical outcomes in breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Vail Health Shaw Cancer Center, Edwards, Colorado
Conditions: Radiation Induced Fibrosis
Register for Updates